Fairmount Funds Management
Latest statistics and disclosures from Fairmount Funds Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are DMRA, DNTH, COGT, SYRE, ORKA, and represent 74.75% of Fairmount Funds Management's stock portfolio.
- Added to shares of these 3 stocks: DMRA (+$226M), DNTH (+$34M), ZBIO.
- Started 1 new stock position in DMRA.
- Reduced shares in these 5 stocks: APGE (-$147M), COGT (-$135M), NUVL (-$73M), ELVN (-$73M), KNSA (-$54M).
- Sold out of its positions in NUVL, KNSA.
- Fairmount Funds Management was a net seller of stock by $-220M.
- Fairmount Funds Management has $1.4B in assets under management (AUM), dropping by 5.37%.
- Central Index Key (CIK): 0001802528
Tip: Access up to 7 years of quarterly data
Positions held by Fairmount Funds Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Fairmount Funds Management
Fairmount Funds Management holds 12 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Damora Therapeutics Com New (DMRA) | 16.3 | $226M | NEW | 8.7M | 25.90 |
|
| Dianthus Therapeutics (DNTH) | 15.4 | $213M | +18% | 2.5M | 83.92 |
|
| Cogent Biosciences (COGT) | 15.3 | $212M | -38% | 5.5M | 38.49 |
|
| Spyre Therapeutics Com New (SYRE) | 14.6 | $203M | 4.0M | 50.44 |
|
|
| Oruka Therapeutics (ORKA) | 13.1 | $182M | 3.7M | 49.05 |
|
|
| Miragen Therapeutics (VRDN) | 5.5 | $77M | 3.9M | 19.56 |
|
|
| Enliven Therapeutics (ELVN) | 5.3 | $73M | -50% | 1.9M | 39.20 |
|
| Jade Biosciences Com New (JBIO) | 4.6 | $64M | 4.6M | 14.05 |
|
|
| Crescent Biopharma (CBIO) | 3.6 | $51M | 2.7M | 18.37 |
|
|
| Zenas Biopharma (ZBIO) | 3.3 | $46M | +6% | 2.4M | 19.55 |
|
| Apogee Therapeutics (APGE) | 1.8 | $25M | -85% | 299k | 84.17 |
|
| Inhibikase Therapeutics Com New (IKT) | 1.0 | $15M | 8.6M | 1.68 |
|
Past Filings by Fairmount Funds Management
SEC 13F filings are viewable for Fairmount Funds Management going back to 2019
- Fairmount Funds Management 2026 Q1 filed May 15, 2026
- Fairmount Funds Management 2025 Q4 filed Feb. 17, 2026
- Fairmount Funds Management 2025 Q3 filed Nov. 14, 2025
- Fairmount Funds Management 2025 Q2 filed Aug. 14, 2025
- Fairmount Funds Management 2025 Q1 filed May 15, 2025
- Fairmount Funds Management 2024 Q4 filed Feb. 14, 2025
- Fairmount Funds Management 2024 Q3 filed Nov. 14, 2024
- Fairmount Funds Management 2024 Q2 filed Aug. 14, 2024
- Fairmount Funds Management 2024 Q1 filed May 15, 2024
- Fairmount Funds Management 2023 Q4 filed Feb. 14, 2024
- Fairmount Funds Management 2023 Q3 filed Nov. 14, 2023
- Fairmount Funds Management 2023 Q2 filed Aug. 14, 2023
- Fairmount Funds Management 2023 Q1 filed May 15, 2023
- Fairmount Funds Management 2022 Q4 filed Feb. 14, 2023
- Fairmount Funds Management 2022 Q3 filed Nov. 9, 2022
- Fairmount Funds Management 2022 Q2 filed Aug. 15, 2022